Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer

被引：1
|
作者：
Yamaguchi, Teppei [1 ]
Hida, Toyoaki [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷 / 08期
关键词：
PHASE-III; MAINTENANCE BEVACIZUMAB; CHEMOTHERAPY; COMBINATION; NIVOLUMAB; DOCETAXEL; EFFICACY; THERAPY; SAFETY;
D O I：
10.21037/tcr.2019.12.57
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E11 / E14
页数：4
相关论文
共 50 条
  • [41] A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL)
    Nogami, Naoyuki
    Kubo, Toshio
    Bessho, Akihiro
    Sakugawa, Makoto
    Ikeo, Satoshi
    Yokoyama, Toshihide
    Seki, Nobuhiko
    Ochiai, Ryosuke
    Fujimoto, Nobukazu
    Murakami, Shuji
    Kaira, Kyoichi
    Harada, Toshiyuki
    Kishino, Daizo
    Takiguchi, Yuichi
    Shimokawa, Tsuneo
    Kiura, Katsuyuki
    Yamashita, Natsumi
    Okamoto, Hiroaki
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (07) : 805 - 812
  • [42] Phase I/II Trial of Carboplatin, nab-Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of Phase I Part
    Ikeo, Satoshi
    Nogami, Naoyuki
    Kitajima, Hiromoto
    Yoshioka, Hiroshige
    Bessho, Akihiro
    Kaira, Kyoichi
    Kubo, Toshio
    Murakami, Shuji
    Watanabe, Koshiro
    Kiura, Katsuyuki
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S905 - S905
  • [43] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
    Motohiro Tamiya
    Akihiro Tamiya
    Hidekazu Suzuki
    Yoshihiko Taniguchi
    Kanako Katayama
    Shojiro Minomo
    Keiko Nakao
    Naoko Takeuchi
    Yoshinobu Matsuda
    Yujiro Naito
    Takayuki Shiroyama
    Norio Okamoto
    Kyoichi Okishio
    Toru Kumagai
    Shinji Atagi
    Fumio Imamura
    Tomonori Hirashima
    [J]. Investigational New Drugs, 2021, 39 : 1106 - 1112
  • [44] A Phase I Trial of Weekly Nab-paclitaxel Plus Carboplatin With Thoracic Radiotherapy for Non-small Cell Lung Cancer
    Kubota, Tetsuya
    Sakai, Mizu
    Anabuki, Kazuki
    Takamatsu, Kazufumi
    Mukaida, Kenichi
    Kobayashi, Kana
    Yamagami, Takuji
    Yokoyama, Akihito
    [J]. IN VIVO, 2024, 38 (01): : 259 - 263
  • [45] Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC).
    Hawkins, M. J.
    Georgy, M.
    Makhson, A.
    Cheporov, S.
    Sergey, O.
    Yablonsky, P.
    Bhar, P.
    Socinski, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 397S - 397S
  • [46] Dose and schedule modifications of carboplatin plus nab-paclitaxel for elderly patients with squamous non-small cell lung cancer from the CAPITAL study
    Saito, G.
    Kogure, Y.
    Kada, A.
    Hashimoto, H.
    Atagi, S.
    Takiguchi, Y.
    Saka, H.
    Ebi, N.
    Inoue, A.
    Kurata, T.
    Yamanaka, T.
    Ando, M.
    Shibayama, T.
    Itani, H.
    Nishii, Y.
    Fujita, Y.
    Yamamoto, N.
    Gemma, A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1020 - S1021
  • [47] Bevacizumab plus Weekly Paclitaxel with or Without Carboplatin for Previously-treated Non-squamous Non-Small Cell Lung Cancer
    Hata, Akito
    Katakami, Nobuyuki
    Tanaka, Kosuke
    Takeshita, Jumpei
    Matsumoto, Takeshi
    Monden, Kazuya
    Nagata, Kazuma
    Masago, Katsuhiro
    Kaji, Reiko
    Fujita, Shiro
    Tachikawa, Ryo
    Otsuka, Kyoko
    Otsuka, Kojiro
    Tomii, Keisuke
    [J]. ANTICANCER RESEARCH, 2014, 34 (1A) : 275 - 281
  • [48] Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
    Govindan, Ramaswamy
    Lind, Mike
    Insa, Amelia
    Khan, Saad A.
    Uskov, Dmitry
    Tafreshi, Ali
    Guclu, Salih
    Bar, Jair
    Kato, Terufumi
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Hansen, Olfred
    Biesma, Bonne
    Kundu, Madan G.
    Dunbar, Martin
    He, Lei
    Ansell, Peter
    Sehgal, Vasudha
    Huang, Xin
    Glasgow, Jaimee
    Bach, Bruce A.
    [J]. CLINICAL LUNG CANCER, 2022, 23 (03) : 214 - 225
  • [49] Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer
    Paladini, Luciano
    Pereira da Veiga, Cassia Rita
    Cerqueira, Erica
    Haas, Laura Chabrol
    Abadi, Marcia Datz
    Baldotto, Clarissa Serodio
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1185 - 1193
  • [50] Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients
    Takeoka, Hiroaki
    Yamada, Kazuhiko
    Naito, Yoshiko
    Matsuo, Norikazu
    Ishii, Hidenobu
    Tokito, Takaaki
    Azuma, Koichi
    Ichiki, Masao
    Hoshino, Tomoaki
    [J]. ANTICANCER RESEARCH, 2018, 38 (06) : 3779 - 3784
12345